Daraxonrasib doubles median survival in pancreatic cancer trial, FDA grants early access

An international study presented at the American Society of Clinical Oncology meeting in Chicago showed that patients with pancreatic cancer who received daraxonrasib lived an average of 13.2 months, compared with roughly 6.6 to 6.7 months for those treated with chemotherapy alone.

The promising survival benefit prompted the U.S. Food and Drug Administration, just a month earlier, to issue an early‑access authorization for daraxonrasib, allowing selected patients who have exhausted standard therapies to obtain the drug.

Co‑founders of Darwin Health, who authored the opinion piece, emphasized that while the results are encouraging, substantial work remains to translate such advances into broader clinical impact, noting that artificial intelligence will play a key role in future breakthroughs.